Literature DB >> 9873611

Synthesis and biological activity of novel thiazolidinediones.

C Prabhakar1, G Madhusudhan, K Sahadev, C M Reddy, M R Sarma, G O Reddy, R Chakrabarti, C S Rao, T D Kumar, R Rajagopalan.   

Abstract

Novel compounds having a dual pharmacophore were synthesised and evaluated for their insulin sensitiser and anti-inflammatory properties in different animal models.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9873611     DOI： 10.1016/s0960-894x(98)00485-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  5 in total

1.  Peroxisome Proliferator-Activated Receptors as Superior Targets for Treating Diabetic Disease, Design Strategies - Review Article.

Authors:  Mohammed T Qaoud; Ihab Almasri; Tijen Önkol
Journal:  Turk J Pharm Sci       Date:  2022-06-27

2.  A green, multicomponent, regio- and stereo-selective 1,3-dipolar cycloaddition of azides and azomethine ylides generated in situ with bifunctional dipolarophiles using PEG-400.

Authors:  Jayant Sindhu; Harjinder Singh; J M Khurana
Journal:  Mol Divers       Date:  2014-02-28       Impact factor: 2.943

3.  Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones.

Authors:  Radhe Shyam Bahare; Swastika Ganguly; Kiattawee Choowongkomon; Supaporn Seetaha
Journal:  Daru       Date:  2015-01-24       Impact factor: 3.117

Review 4.  Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs.

Authors:  Neelaveni Thangavel; Mohammed Al Bratty; Sadique Akhtar Javed; Waquar Ahsan; Hassan A Alhazmi
Journal:  Int J Med Chem       Date:  2017-06-05

Review 5.  An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes.

Authors:  Garima Bansal; Punniyakoti Veeraveedu Thanikachalam; Rahul K Maurya; Pooja Chawla; Srinivasan Ramamurthy
Journal:  J Adv Res       Date:  2020-01-22       Impact factor: 10.479
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.